CardioCell reports positive Phase IIa trial results of itMSCs to treat chronic heart failure
US-based biotechnology company CardioCell has reported positive results from its Phase IIa clinical trial of ischemia-tolerant mesenchymal stem cells (itMSCs) for chronic heart failure (HF).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Cardiology | Clinical Trials | Heart | Heart Failure | Pharmaceuticals | Stem Cell Therapy | Stem Cells